Daniel Tasse
CIK 1502785 · CHIEF EXECUTIVE OFFICER · last filed 2026-06-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$489.9K
Companies
3
Total Filings
24
Lifetime Open-Market Net
$314.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RGNX | Director | 28,861 | $6.66 | $192.2K | $0 | 11 | 2026-06-02 |
| DBVT | CHIEF EXECUTIVE OFFICER | 17,094 | $17.41 | $297.7K | $14.2K | 6 | 2025-11-24 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | Director | 182,604 | $0.01 | $2.2K | $300.0K | 7 | 2018-06-25 |
Recent Filings · Page 3 of 3
24 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-08-16 | RGNX | Grant (A) | — | $0 | EDGAR |
| 2016-06-21 | Bellerophon Therapeutics, Inc. (BLPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-04-29 | Bellerophon Therapeutics, Inc. (BLPH) Delisted | Grant (A) | +16,356 | $0 | EDGAR |
| 2015-02-23 | Bellerophon Therapeutics, Inc. (BLPH) Delisted | Buy (P) | +25,000 | $300.0K | EDGAR |
Showing 21–24 of 24
Prev
Page 3 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.